Q-omics provides the consensus-scored DPYD-AS2 profile across patient tissues and cancer cell-line models. DPYD-AS2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, DPYD-AS2 is differentially expressed in 2, with the highest sampling consensus in STAD. Additionally, DPYD-AS2 RNA expression shows 16,563 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, STAD, and LSCC as cancer lineages where DPYD-AS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DPYD-AS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DPYD-AS2 survival associations across molecular data types. DPYD-AS2 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DPYD-AS2 RNA expression–survival associations across cancer types. High DPYD-AS2 expression shows unfavorable associations in KICH, THYM, READ, UVM and DLBC, but favorable associations in MESO. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for DPYD-AS2 RNA expression.
This table summarizes DPYD-AS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for DPYD-AS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DPYD-AS2 shows lower tumor expression in UCEC and higher tumor expression in STAD. The STAD box plot shows higher DPYD-AS2 RNA expression in tumor versus normal tissue (log2 FC = +0.062, t-test p = .029).
This table shows molecular features associated with DPYD-AS2 in patient tissues and cancer cell lines. In patient samples, DPYD-AS2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
